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Abstract For many years, prorenin has been considered to
be nothing more than the inactive precursor of renin. Yet,
its elevated levels in diabetic subjects with microvascular
complications and its extrarenal production at various sites
in the body suggest otherwise. This review discusses the
origin, regulation, and enzymatic activity of prorenin, its
role during renin inhibition, and the angiotensin-dependent
and angiotensin-independent consequences of its binding to
the recently discovered (pro)renin receptor. The review
ends with the concept that prorenin rather than renin





Despite nearly 40 years of research on prorenin, the renin
precursor is still the least well-understood component of the
renin–angiotensin system (RAS). Initially, it was thought to
have no function at all. Yet, it circulates in human plasma in
excess to renin, sometimes at concentrations that are 100
times higher, and in plasma of anephric subjects, prorenin,
but not renin, is still present [1, 2]. This suggests that
prorenin, in contrast with renin, is also of extrarenal origin.
Prorenin is particularly elevated in diabetic subjects with
microvascular complications [3]. Moreover, the renal
vasodilator response to captopril in diabetic subjects cor-
related better with plasma prorenin rather than with plasma
renin [4]. Thus, (circulating) prorenin may have a function
after all. Possibly, it is prorenin (and not renin) which is
responsible for tissue angiotensin generation. Obviously,
this would require local prorenin–renin conversion, for
which no evidence exists [5]. In support of this concept,
however, transgenic rodents with (inducible) prorenin
expression in the liver display increased cardiac angiotensin
(Ang) I levels, cardiac hypertrophy, and/or vascular damage
[6, 7].
Origin and regulation of prorenin
The juxtaglomerular epithelioid cells, located in the walls
of renal afferent arterioles, are the main source of renin in
the body. Renin is synthesized as preprorenin. Preprorenin
is converted to prorenin upon insertion into the endoplas-
matic reticulum. The majority (75%) of prorenin is secreted
constitutively, while the remainder is targeted to dense core
secretory granules. In these granules, an acidic pH is
created to optimize the activity of the proteases (cathepsin
B, prohormone convertases) that cleave off the prosegment
to yield renin. Prorenin and renin levels are highly
correlated but do not alter in parallel under all circum-
stances [1]. Acute stimuli of renin will not affect prorenin
levels, whereas chronic stimuli (like a decrease in Ang II)
increase both renin and prorenin. This suggests that renin is
stored as active enzyme and is released immediately upon
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e-mail: a.danser@erasmusmc.nlstimulation of the juxtaglomerular apparatus. Prorenin is
released constitutively, and no acute responses occur.
Chronic stimulation causes more prorenin to be converted
to renin, leading to an increased renin/prorenin ratio in
plasma. However, some exceptions to this rule exist. A
well-known example is, as mentioned above, diabetes
mellitus complicated by retinopathy and nephropathy [3].
Pregnant women also have high plasma prorenin levels,
derived from the ovaries [8]. The function of this prorenin
is unknown, as is the function of prorenin in amniotic fluid,
in which prorenin was discovered. The reproductive organs,
together with the adrenal, eye, and submandibular gland,
are sites of extrarenal renin gene expression [9]. For reasons
that are not understood, these tissues predominantly, if not
exclusively, synthesize and release prorenin.
Enzymatic activity of prorenin?
A 43-amino-acid N-terminal propeptide explains the ab-
sence of enzymatic activity of prorenin. This propeptide
covers the enzymatic cleft and obstructs access of angio-
tensinogen to the active site of renin. Prorenin can be
activated in two ways: proteolytic or nonproteolytic [10].
Proteolytic activation is irreversible: it involves actual
removal of the propeptide. Nonproteolytic activation of
prorenin is reversible. It can best be imagined as an
unfolding of the propeptide from the enzymatic cleft.
Nonproteolytic activation can be induced by exposure to
low pH (pH=3.3) or cold (4°C) [10]. Nonproteolytically
activated prorenin is enzymatically active and can be
recognized by monoclonal antibodies that are specific for
the active site. Kinetic studies of the nonproteolytic
activation process have indicated that an equilibrium exists
between the closed (inactive) and open (active) forms of
prorenin. The inactivation step is highly temperature
dependent and occurs very rapidly at neutral pH and 37°C.
Consequently, under physiological conditions, <2% of
prorenin is in the open and active form, i.e., displays
enzymatic activity, and >98% is closed and inactive.
Prorenin receptor(s)?
The beneficial effects of RAS blockers are due, at least in
part, to blockade of the generation or action of Ang II at
tissue sites [11]. In tissues that are believed not to express
the renin gene, like the heart and vascular wall, such
angiotensin generation depends on renin/prorenin taken up
from the circulation. Simple diffusion cannot explain the
relatively high renin levels in these organs, and thus a
receptor-mediated mechanism may exist. Two candidates
currently have been proposed: the mannose 6-phosphate/
insulin-like growth factor II receptor (M6P/IGF2R) [12–14]
and the (pro)renin receptor [15]. The M6P/IGF2R non-
selectively binds M6P-containing proteins like renin and
prorenin. However, such binding did not result in angio-
tensin generation, and it is now believed that the M6P/
IGF2R is a clearance receptor for renin/prorenin [16]. This
leaves the (pro)renin receptor as the most promising
candidate for tissue uptake of circulating renin/prorenin.
This receptor, a 350-amino-acid protein with a single
transmembrane domain, binds prorenin with higher affinity
than renin [17] and, unlike the M6P/IGF2R, does not
internalize these proteins. Interestingly, binding to the
receptor allowed prorenin to become catalytically active
without proteolytic cleavage of the prosegment [15, 17].
Apparently, therefore, binding induces a conformational
change in the prorenin molecule, similar to the change
occurring after exposure to cold or low pH.
Angiotensin-independent effects of prorenin?
After the discovery of the receptor, (pro)renin receptor an-
tagonists were designed based on the idea that the prosegment
Fig. 1 Model depicting prorenin
activation by the (pro)renin
receptor (P)RR, allowing prorenin
to generate angiotensin I from
angiotensinogen. In addition, pro-
renin binding to the receptor
results in effects (intracellular sig-
naling) that are independent of
angiotensin generation. HRP is
assumed to block both prorenin
activation and the direct prorenin-
inducedeffects(seetextforfurther
explanation)
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These (peptidic) antagonists (also known as ‘handle region
peptides’, HRP) mimic the handle region and thus may bind
to the receptor instead of prorenin. In support of this concept,
HRP infusion normalized the elevated renal angiotensin
content in diabetic rats [18] and simultaneously prevented
the development of diabetic nephropathy.
Surprisingly, identical effects occurred in diabetic angio-
tensin II type 1A receptor-deficient mice [19]. Since such
mice no longer display the normal (constrictor) response to
Ang II [20], the effect of the (pro)renin receptor antagonist
in these mice cannot be due to suppression of local an-
giotensin generation. Thus, prorenin may also exert direct
angiotensin-independent effects, possibly via the above
described (pro)renin receptor (Fig. 1). Indeed, prorenin
(and renin) induced p42/p44 mitogen-activated protein
kinase (MAPK) activation and transforming growth fac-
tor-β1 release in mesangial cells [15, 21], and these effects
did not occur following deletion of the receptor with siRNA
[21]. Moreover, in cardiomyocytes, prorenin concentration
dependently activated p38 MAPK and phosphorylated heat
shock protein 27 [22].
Overexpression of the human (pro)renin receptor in rats
resulted in elevated blood pressure, increased plasma al-
dosterone, and/or glomerulosclerosis [23, 24]. Since such
overexpression was not accompanied by changes in renin
or Ang II, angiotensin-independent effects of the receptor
may underlie this phenotype. HRP prevented the develop-
ment of glomerulosclerosis in (pro)renin receptor transgenic
rats [25]. Yet, transgenic rats with inducible hepatic pro-
renin expression (resulting in a >200-fold rise in plasma
prorenin) did not develop glomerulosclerosis [26], although
such animals did develop hypertension. Moreover, HRP
blocked neither prorenin binding to cells overexpressing the
human (pro)renin receptor [17] nor prorenin-induced
signaling in U937 monocytes [27]. Thus, it is uncertain to
what degree the beneficial in vivo effects of HRP are solely
due to prorenin blockade. Such effects are unlikely to
involve renin, since HRP will not block renin–(pro)renin
receptor interaction.
Prorenin and renin inhibition
Prorenin levels will rise during renin inhibition, as they do
during any type of RAS blockade. Renin inhibitors affect
the equilibrium between the open and closed forms of
prorenin, because such drugs (due to their high affinity for
the active site) prevent inactivation [10]. Therefore, renin
inhibitors, like low pH, cold, and the (pro)renin receptor,
are capable of nonproteolytically ‘activating’ prorenin al-
though, of course, due to the presence of the renin inhibitor,
this open prorenin cannot display enzymatic activity. Open
prorenin will however be recognized by the active site-
directed antibodies applied in renin immunoradiometric
assays, thus leading to an overestimation of the renin rise
during renin inhibition [28].
Theoretically, the elevated (pro)renin levels during renin
inhibition might result in (pro)renin receptor activation. In
vitro studies suggest that renin inhibitors do not interfere
with this process. The consequence of such overstimulation
is unknown. However, since such a rise also occurs during
other types of RAS blockade, its detrimental effects, if
present, should have been known by now. A possible
explanation comes from the work of Schefe et al. [29], who
showed that, on activation of the receptor, the transcription
factor promyelocytic zinc finger is translocated to the
nucleus and represses transcription of the (pro)renin
receptor itself, thus creating a short negative feedback loop.
In other words, high (pro)renin levels, as occurring during
RAS blockade, will suppress (pro)renin receptor expres-
sion, thereby preventing excessive receptor activation.
Furthermore, the members of a family with a mutated renin
allele, resulting in high plasma prorenin levels, were
phenotypically normal [30].
Conclusion
After many years, it now seems that a function for prorenin
has been found. The ‘inactive’ renin precursor gains Ang
I-generating activity by binding to a receptor, without
undergoing proteolytic cleavage. This mechanism explains
how prorenin might contribute to tissue angiotensin
generation, even when no prorenin–renin conversion occurs
outside the kidney. Renin inhibitors will bind to such open
activated prorenin, to the same degree as they bind to renin,
and may thus be the ideal tools to block tissue angiotensin
generation. In vitro studies suggest that prorenin also acts
as an agonist of the (pro)renin receptor, inducing intracel-
lular signaling pathways in an angiotensin-independent
manner. However, given the contradictory data obtained
with the (pro)renin receptor blocker HRP, more work is
needed to verify the in vivo importance of such prorenin-
induced (pro)renin receptor activation.
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